Human monoclonal antibody specific for lipopolysaccharides (LPS) of the
The present invention relates to a human monoclonal antibody specific for the serotype IATS O11 of P. aeruginosa , a hybridoma producing it, nucleic acids encoding it, and host cells transfected therewith. Further, the present invention relates to methods for producing said monoclonal antibody. In addition, the present invention relates to pharmaceutical compositions comprising at least one antibody or at least one nucleic acid encoding said antibody.
1. A human monoclonal antibody specific for lipopolysaccharide (LPS) of the P. aeruginosa LPS serotype IATS 011 wherein the variable region of the light chain of the antibody has the amino acid sequence of SEQ ID NO:7 and the variable region of the heavy chain has the amino acid sequence of SEQ ID NO:8; or a variant of said antibody capable of binding said LPS wherein the amino acid sequence of the variable region of the light chain of the antibody is at least 85% homologous to SEQ ID NO:7 and the amino acid sequence of the variable region of the heavy chain of the antibody is at least 85% homologous to SEQ ID NO:8.
2. The human monoclonal antibody of claim 1 , wherein the light chain is of the kappa type.
3. The human monoclonal antibody of claim 1 , wherein the light chain is of the lambda type.
4. The human monoclonal antibody of claim 1 , wherein the heavy chain is of the IgM, IgA or IgG type.
5. The human monoclonal antibody of claim 4 , wherein the heavy chain is of the IgM type.
6. The human Monoclonal antibody of claim 1 , wherein the antibody consists entirely of human amino acid sequence.
7. The human monoclonal antibody of claim 1 , wherein the antibody exhibits essentially human antigen recognition.
8. The human monoclonal antibody of claim 1 , wherein the antibody comprises a modification selected from the group consisting of oligomerization, conjugation to a drug, and conjugation to a label.
9. A hybridoma capable of producing the human monoclonal antibody of claim 1 .
10. An isolated host cell capable of producing the human monoclonal antibody of claim 1 .
11. A pharmaceutical composition comprising at least one human monoclonal antibody of claim 1 and optionally pharmaceutically acceptable ingredients.
12. A method of protecting a human patient from P. aeruginosa infection or treating a P. aeruginosa infection in a human patient, said method comprising administering the human monoclonal antibody of claim 1 to said human patient.
13. The method of claim 12 wherein the P. aeruginosa infection is a hospital-acquired infection.
14. A test kit for the diagnosis of a P. aeruginosa infection in a sample comprising at least one human monoclonal antibody of claim 1 and optionally further suitable ingredients for carrying out the diagnostic test.